Cargando…
Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients
OBJECTIVE: Determine if patient-specific factors modulate absolute lymphocyte count (ALC), neutrophil count (ANC), and/or Neutrophile-lymphocyte ratio (NLR) in Dimethyl Fumarate (DMF) treated patients. METHODS: A retrospective study of patients who initiated DMF between 2013–2018. A multicenter stud...
Autores principales: | Goldman, Myla D., Dwyer, Lauren, Coleman, Rachael, Sohn, Min-Woong, Stuve, Olaf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012426/ https://www.ncbi.nlm.nih.gov/pubmed/32045436 http://dx.doi.org/10.1371/journal.pone.0228617 |
Ejemplares similares
-
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018) -
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017) -
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations
por: Fox, Robert J., et al.
Publicado: (2016) -
Interventions to Increase Leukocyte Testing during Treatment with Dimethyl Fumarate
por: Heidenreich, Paul A., et al.
Publicado: (2021) -
Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
por: Sattarnezhad, Neda, et al.
Publicado: (2022)